These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8308965)

  • 1. Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: a 5-year followup.
    Srougi M; Simon SD
    J Urol; 1994 Mar; 151(3):593-7. PubMed ID: 8308965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
    Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: long-term followup of a prospective study.
    de la Rosa F; Garcia-Carbonero R; Passas J; Rosino A; Lianes P; Paz-Ares L
    J Urol; 2002 Jun; 167(6):2413-8. PubMed ID: 11992048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer.
    Donat SM; Herr HW; Bajorin DF; Fair WR; Sogani PC; Russo P; Sheinfeld J; Scher I
    J Urol; 1996 Aug; 156(2 Pt 1):368-71. PubMed ID: 8683681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
    J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant cisplatin, methotrexate and vinblastine for muscle-invasive bladder cancer: long-term followup.
    Dreicer R; Kollmorgen TA; Smith RF; Williams RD
    J Urol; 1993 Sep; 150(3):849-52. PubMed ID: 8345598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive bladder cancer: a single-institution experience with bladder-sparing approach.
    Zapatero A; Martín de Vidales C; Marín A; Cerezo L; Arellano R; Rabadán M; Pérez-Torrubia A
    Int J Cancer; 2000 Oct; 90(5):287-94. PubMed ID: 11091353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer.
    Nieuwenhuijzen JA; Bex A; Meinhardt W; Kerst JM; Schornagel JH; VAN Tinteren H; Horenblas S
    J Urol; 2005 Jul; 174(1):80-5. PubMed ID: 15947583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder.
    Sternberg CN; Arena MG; Calabresi F; De Carli P; Platania A; Zeuli M; Giannarelli D; Cancrini A; Pansadoro V
    Cancer; 1993 Sep; 72(6):1975-82. PubMed ID: 8364877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.
    Tester W; Caplan R; Heaney J; Venner P; Whittington R; Byhardt R; True L; Shipley W
    J Clin Oncol; 1996 Jan; 14(1):119-26. PubMed ID: 8558186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
    J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group.
    Splinter TA; Scher HI; Denis L; Bukowski R; Simon S; Klimberg I; Soloway M; Vogelzang NJ; van Tinteren H; Herr H
    J Urol; 1992 Mar; 147(3):606-8. PubMed ID: 1538438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study.
    Fellin G; Graffer U; Bolner A; Ambrosini G; Caffo O; Luciani L
    Br J Urol; 1997 Jul; 80(1):44-9. PubMed ID: 9240179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome.
    Herr HW; Bajorin DF; Scher HI
    J Clin Oncol; 1998 Apr; 16(4):1298-301. PubMed ID: 9552029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy for invasive bladder carcinoma: disease outcome and bladder preservation and relationship to local tumor response.
    Hatcher PA; Hahn RG; Richardson RL; Zincke H
    Eur Urol; 1994; 25(3):209-15. PubMed ID: 8200403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of neoadjuvant chemotherapy in invasive bladder cancer.
    Cam K; Yildirim A; Ozveri H; Turkeri L; Akdas A
    Int Urol Nephrol; 2002; 33(1):49-52. PubMed ID: 12090338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
    Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
    Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.